EXEL vs LLY

Exelixis continues to demonstrate robust financial performance, driven by its flagship oncology drug, Cabometyx, which showed an 8.1% YoY increase in net product revenues. The company's Q1 2026 results exceeded EPS consensus and delivered strong YoY net income growth of 31.9%. A significant catalyst is the FDA's acceptance of the NDA for zanzalintinib (XL092) in metastatic colorectal cancer, with ...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...